XML 62 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation - Non-options (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Weighted average price            
Share-based compensation costs recognized   $ 4,014 $ 4,483 $ 15,015 $ 12,790  
BTI RSU            
Number of shares            
Outstanding, beginning balance (in shares)       119,000    
Granted (in shares) 25,000     133,000 122,000  
Vested (in shares)       (61,000)    
Outstanding, ending balance (in shares)   191,000 119,000 191,000 119,000 119,000
Weighted average price            
Granted, Weighted average price (in dollars per share)       $ 19.62   $ 13.97
Vesting period       4 years 4 years  
Vesting (as a percent)       25.00% 25.00%  
BTI RSU | Employee            
Weighted average price            
Vesting period 1 year          
BTI RSU | Nonemployee consultant            
Weighted average price            
Vesting (as a percent) 50.00%          
BTI RSU | Grant Date 2023            
Weighted average price            
Unrecognized stock-based compensation expense   $ 2,255   $ 2,255    
BTI RSU | Grant Date 2022            
Weighted average price            
Unrecognized stock-based compensation expense   $ 841   $ 841    
OnkosXcel PSUs            
Number of shares            
Outstanding, beginning balance (in shares)       1,310    
Granted (in shares)       30    
Cancelled (in shares)       (10)    
Forfeited (in shares)       (30)    
Outstanding, ending balance (in shares)   1,300   1,300   1,310
Vested aggregate (in shares)   560   560    
Weighted average price            
Outstanding, Weighted average price (in dollars per share)           $ 5,506
Granted, Weighted average price (in dollars per share)       $ 10,176    
Cancelled, Weighted average price (in dollars per share)       5,506    
Forfeited, Weighted average price (in dollars per share)       5,506    
Vested, Weighted average price (in dollars per share)   $ 5,531   $ 5,531    
Vesting period       48 months    
Unrecognized stock-based compensation expense   $ 3,203   $ 3,203    
Weighted average fair value of non-options granted (in dollars per share)       $ 8    
OnkosXcel PSUs | OnkosXcel            
Number of shares            
Granted (in shares)       1,340    
OnkosXcel PSUs | Executive officers            
Weighted average price            
Vesting period       24 months    
OnkosXcel RSUs            
Number of shares            
Granted (in shares)       225    
Outstanding, ending balance (in shares)   225   225    
Weighted average price            
Granted, Weighted average price (in dollars per share)       $ 10    
Unrecognized stock-based compensation expense   $ 2,151   $ 2,151    
OnkosXcel RSUs | Tranche One            
Number of shares            
Granted (in shares)       125,000    
Weighted average price            
Vesting period       180 days    
OnkosXcel RSUs | Tranche Two            
Weighted average price            
Vesting period       4 years    
Vesting (as a percent)       25.00%